News

Pharmabiz2m
US FDA clears Hemispherian’s IND application for first-in-class glioblastoma therapeutic, GLIX1
US FDA clears Hemispherian’s IND application for first-in-class glioblastoma therapeutic, GLIX1: Oslo, Norway Wednesday, August 6, 2025, 15:00 Hrs [IST] Hemispherian AS, a pione ...
Pharmabiz7h
DISSO ASIA 2025, Jakarta initiates India–Indonesia scientific collaboration
DISSO ASIA 2025, Jakarta initiates India–Indonesia scientific collaboration: Shardul Nautiyal, Mumbai Wednesday, August 6, ...
Pharmabiz32m
Lupin reports 51.5 per cent growth in net profit during Q1FY26
Lupin reports 51.5 per cent growth in net profit during Q1FY26: Our Bureau, New Delhi Wednesday, August 6, 2025, 14:30 Hrs [IST] Lupin Ltd has posted a growth of 51.5 per cent in ...
Pharmabiz47m
Medistep Healthcare's IPO to open on August 8; Issue price fixed at Rs. 43 per share
Medistep Healthcare's IPO to open on August 8; Issue price fixed at Rs. 43 per share: Our Bureau, Mumbai Wednesday, August 6, 2025, 14:15 Hrs [IST] Medistep Healthcare Limited, a ...
Pharmabiz1h
Innovent Biologics receives US FDA clearance to initiate phase 1 clinical trial of novel oral GLP-1R agonist, IBI3032
Innovent Biologics receives US FDA clearance to initiate phase 1 clinical trial of novel oral GLP-1R agonist, IBI3032: San Francisco Wednesday, August 6, 2025, 14:00 Hrs [IST] Inn ...
Pharmabiz2h
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes: Boston Wednesday, August 6, 2025, 13:00 Hrs [IST] SOPHiA GENETICS, a clo ...
Pharmabiz1h
Laborate Pharmaceuticals secures EU-GMP certification, expands global supply chain capabilities
Laborate Pharmaceuticals secures EU-GMP certification, expands global supply chain capabilities: Our Bureau, Mumbai Wednesday, August 6, 2025, 13:30 Hrs [IST] Laborate Pharmaceuti ...
Pharmabiz3h
US FDA accepts for priority review Bristol Myers Squibb’s sBLA for Breyanzi to treat adult patients with relapsed or refractory MZL
US FDA accepts for priority review Bristol Myers Squibb’s sBLA for Breyanzi to treat adult patients with relapsed or refractory MZL: Princeton, New Jersey Wednesday, August 6, 2 ...
Pharmabiz4h
Polpharma Biologics & Fresenius Kabi enter licensing agreement for proposed vedolizumab biosimilar, PB016
Polpharma Biologics & Fresenius Kabi enter licensing agreement for proposed vedolizumab biosimilar, PB016: Amsterdam Wednesday, August 6, 2025, 11:00 Hrs [IST] Polpharma Biologics ...
Pharmabiz5h
Ascletis completes enrollment in US phase IIa study of small molecule oral GLP-1R agonist, ASC30 to treat obesity
Ascletis completes enrollment in US phase IIa study of small molecule oral GLP-1R agonist, ASC30 to treat obesity: Hong Kong Wednesday, August 6, 2025, 10:00 Hrs [IST] Ascletis Ph ...
Pharmabiz6h
BD businesses become first in medtech to achieve HIRC's Diamond Badge across all supply chain resiliency categories
BD businesses become first in medtech to achieve HIRC's Diamond Badge across all supply chain resiliency categories: Franklin Lakes, New Jersey Wednesday, August 6, 2025, 09:00 Hr ...
Pharmabiz7h
Info for participants displayed on e-platform should be approved by EC
We plan to host an electronic platform for inviting patients to join clinical trials. We are interested in incorporating testimonials from patients and healthcare professionals (HCP) onto the website.